Procurement Summary
Country: Denmark
Summary: Amgros 2027 1.614.B
Deadline: 06 Oct 2026
Posting Date: 20 Aug 2026
Other Information
Notice Type: Tender
TOT Ref.No.: 147562478
Document Ref. No.:
Competition: ICB
Financier: Self Financed
Purchaser Ownership: Public
Tender Value: Refer Document
CPV Classification
33600000 - Pharmaceutical products
Purchaser's Detail
Name: Login to see tender_details
Address: Login to see tender_details
Email: Login to see tender_details
Login to see detailsTender Details
Subcontract: LOT-0001 Title: Tender number 1 Description: Amgros I/S (Amgros) is a partnership with the 5 regions as stakeholders. Amgros wishes to enter into framework agreements for the medicines that appear in the individual sub-contracts below, with a view to supply the hospital pharmacies of the stakeholders with medicines as well as possible resale to the Faroe Islands and Greenland. Amgros resells the medicines to the hospital pharmacies at Amgros' purchase price with a surcharge. The framework agreements are non-exclusive. The framework agreements are concluded without obligation to purchase, and the hospital pharmacies in the regions are not obliged to use Amgros' framework agreements. CPV code: Medicines [33600000]
Deadline: 2026-10-06 Place of execution: Denmark, City of Copenhagen (DK011) Description: The tender number (part contract) includes the following medicinal products: ATC Code: N03AX14 · Generic name: Levetiracetam · Dispensing form: Tablets · Strength: 250 mg · Unit value: 1.5 g · Quantity in units: 14559. Each tender number is considered an independent sub-contract and is offered independently of the other tender numbers. A supplier can thus choose to make an offer for one, several or all tender numbers, and allocation is made separately for each one tender number. A supplier can thus be awarded one, several or all partial contracts. Reference is made to the tender conditions, including the submission of tenders under the individual tender numbers. Under the designation "quantity in units" above, an estimated consumption is indicated of the medicines under the tender number, but the actual consumption may differ significantly from that. The suppliers must anticipate this. The background for this is that these are medicines for patient treatment in the public hospitals, where the patient's needs must be met accommodated. For a more detailed description, please refer to the tender conditions and the framework agreement.
Documents
Tender Notice